AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 85_CD 8_CD Segment_NN information_NN The_DT Groups_NNS activities_NNS are_VBP in_IN one_CD class_NN of_IN business_NN ,_, pharmaceuticals_NNS ._.
There_EX are_VBP no_DT other_JJ significant_JJ classes_NNS of_IN business_NN ,_, either_CC singularly_RB or_CC in_IN aggregate_NN ._.
Geographic_JJ areas_NNS The_DT tables_NNS below_IN show_NN information_NN by_IN geographic_JJ area_NN and_CC ,_, for_IN turnover_NN and_CC tangible_JJ fixed_VBN assets_NNS ,_, material_NN countries_NNS ._.
The_DT figures_NNS show_VBP the_DT turnover_NN ,_, operating_VBG profit_NN and_CC profit_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN and_CC taxation_NN made_VBN by_IN companies_NNS located_VBN in_IN that_DT area_NN country_NN ,_, together_RB with_IN net_JJ operating_NN assets_NNS and_CC tangible_JJ fixed_VBN assets_NNS owned_VBN by_IN the_DT same_JJ companies_NNS :_: export_NN sales_NNS and_CC the_DT related_JJ profit_NN are_VBP included_VBN in_IN the_DT area_NN country_NN from_IN which_WDT those_DT sales_NNS were_VBD made_VBN ._.
In_IN the_DT US_NNP ,_, sales_NNS to_TO three_CD wholesalers_NNS accounted_VBD for_IN approximately_RB 80_CD %_NN of_IN our_PRP$ US_NNP sales_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 86_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 8_CD Segment_NN information_NN continued_VBD Profit_NN on_IN ordinary_JJ Operating_NN profit_NN activities_NNS before_IN after_IN exceptional_JJ items_NNS interest_NN and_CC taxation_NN 2004 2003 2002 2004_CD 2003_CD 2002_CD Profit_NN from_IN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 1,074_CD 810_CD 672_CD 1,076_CD 812_CD 673_CD Continental_NNP Europe_NNP 2,229_CD 2,241_CD 1,689_CD 2,452_CD 2,241_CD 1,689_CD The_DT Americas_NNPS 1,192_CD 816_CD 1,473_CD 1,192_CD 816_CD 1,473_CD Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP 275 244 172 275_CD 244_CD 172_CD Continuing_VBG operations_NNS 4,770_CD 4,111_CD 4,006_CD 4,995_CD 4,113_CD 4,007_CD Net_NN operating_VBG assets_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 4,429_CD 4,146_CD 3,101_CD Continental_NNP Europe_NNP 5,483_CD 5,771_CD 4,805_CD The_DT Americas_NNPS 2,336_CD 1,931_CD 1,004_CD Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP 1,194_CD 1,033_CD 958_CD Continuing_VBG operations_NNS 13,442_CD 12,881_CD 9,868_CD Net_NN operating_VBG assets_NNS exclude_VBP short_JJ term_NN investments_NNS ,_, cash_NN ,_, short_JJ term_NN borrowings_NNS ,_, loans_NNS and_CC non-operating_JJ debtors_NNS and_CC creditors_NNS ._.
Tangible_JJ fixed_JJ assets_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 2,655_CD 2,502_CD 2,319_CD Sweden_NNP 2,359_CD 2,122_CD 1,626_CD US_NNP 1,153_CD 1,095_CD 1,031_CD Others_NNS 1,916_CD 1,817_CD 1,621_CD Continuing_VBG operations_NNS 8,083_CD 7,536_CD 6,597_CD Geographic_JJ markets_NNS The_DT table_NN below_IN shows_NNS turnover_NN in_IN each_DT geographic_JJ market_NN in_IN which_WDT customers_NNS are_VBP located_VBN ._.
